1.420 s

+0.010 (+0.71%)
Range 1.420 - 1.470   (3.52%)
Open 1.420
Previous Close 1.410
Buy Price 1.430
Buy Volume 12
Sell Price 1.440
Sell Volume 40
Volume 1,829,107
Value -
Remark s
Measurement Type Value
EPS (USD) -0.236
Trailing EPS (USD) -0.315
NAV (USD) 0.55
Cash In Hand (USD) 0.18
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 2.566
Price / Cash In Hand 7.842
Issued & Paid-up Shares 320,599,000
Treasury Shares -
Market Cap (M) 452.045
Par Value (USD) n.a.
Beta - 75 Days 1.239
R-Squared - 75 Days(%) 12.44
Beta - 500 Days 0.794
R-Squared - 500 Days(%) 11.04
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 19 Oct 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 04 Nov 2021
View All Events

About GERON CORP

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.

Loading Chart...